Pfizer Beats Expectations in Q4 2025, Eyes Obesity Drug and Cost Cuts Amid Looming Patent Cliffs
Pfizer reported a mixed fourth quarter, beating internal financial targets while navigating a post-COVID revenue decline. The pharmaceutical giant spotlighted strong growth from new products and a promising monthly obesity drug candidate, even as it braces for a wave of patent expirations and reaffirms its 2026 outlook.